• Cancel
    Date：2020-01

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=435

    CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participation f

  • Cancel
    Date：2019-12

    -

  • Cancel
    Date：2019-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=432

    Denovo Biopharma just recently completed its B-series round of financing raising RMB 300 million with investments from Jiuyo Capital, Sangel Capital, Share Capital, Zheshang Industrial Integration, Yuexiu Capital, Gan Zhan Capital, and Wen Fang Technology

  • Cancel
    Date：2019-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=431

    Vedanta Biosciences is one of the top companies worldwide developing consortia of microbiome with drug-like properties. Vedanta’s self-developed technologies can precisely control these consortia with drug-like properties, thus overcoming the need to deal with the inconsistencies of directly sourced fecal donor material. Vedanta has brought a number of products through clinical testing. The rights of two of Vedanta’s products were sold to large international pharmaceutical companies including BMS and Janssen for further development. This most recent capital raise is an example of a Chinese investment bank raising capital in the Asia Pacific region for a company outside of China. This transaction is a testament to CEC Capital’s strong grasp of internationally cutting-edge technologies as well as its comprehensive investor coverage in the Asia Pacific region.

  • Cancel
    Date：2019-09

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2019-07

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2019-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=425

    The world leader in tumor immunotherapy—Oncologie—has just received USD80 million through its series B financing round. The round was led by Nan Fung Life Sciences and Pivotal BioVentures China. Follow investors included Panacea Ventures, Hualing Capital, Zheshang Industrial Integration Holdings, Jiuyou Fund, Volcanics Ventures, Korea Investment Partners and KB Investment. CEC Capital served as the chief financial adviser to Oncologie during this round of financing.

  • Cancel
    Date：2019-05

    CEC Capital Served as Financial Advisor